Your position:www.healthoo.com >> EN >> EN >> Formulation >> Roche’s phase III INShore study of Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome meets its primary endpoints >> article
 
Roche’s phase III INShore study of Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome meets its primary endpoints
Editor:xuezhe     Clicks:0    Date:2025/10/29 14:44:05
Keyword: Roche
Healthoo Information:
Roche’s phase III INShore study of Gazyva/Gazyvaro in children young adults with idiopathic nephrotic syndrome meets its primary endpoints
 
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68012929
  Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Relative Information
  • Roche finished its Shanghai expansion project
  • Roche formally launched Avastin in China
  • Roche to boost China headcount by 25%
  • Zhong'an Pharma passed FDA inspection
  • Top 15 pharmaceutical firms in 2009
  • Roche expects China to account for half&...
  • Roche announced to expand its facilities ...
  • Roche Chinese R&D center into operation
  • Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
    Tel:+86-10-68032463